Literature DB >> 11194316

New York State pharmacists' attitudes toward needle and syringe sales to injection drug users before implementation of syringe deregulation.

B P Linas1, P O Coffin, G Backes, D Vlahov.   

Abstract

In May 2000, New York State passed legislation permitting the sale, purchase, and possession of up to 10 needles and syringes without a prescription. The law is intended to reduce the transmission of human immunodeficiency virus (HIV) and hepatitis among injection drug users (IDUs), their sexual partners, and their children. To obtain baseline information about the attitudes and likely practices of New York State pharmacists, we distributed a self-administered questionnaire to attendees of the state pharmacy association meeting in June 2000. Of 48 usable responses, 19% were from New York City and the rest from New York State. Of the 48, 42% were unaware of the new law before the day of the survey, and 60% were somewhat or very willing to sell needles and syringes to an IDU. Of those who were not willing to sell to an IDU, 82% cited familiarity of the customer as a very important consideration in their decision making. Those who were not willing to sell to an IDU were more concerned about the detrimental impact of syringe sales on the community, were less likely to be aware of the new law, and were more likely to be concerned about legal liability for syringe sales. Over 80% of all pharmacists believed that syringe sales to IDUs are an important preventive health measure. The majority also favored learning more about the law. Compared to other state surveys of pharmacists, these preliminary data show a similar level of interest in becoming involved with syringe availability programs.

Entities:  

Mesh:

Year:  2000        PMID: 11194316      PMCID: PMC3456767          DOI: 10.1007/BF02344037

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  9 in total

1.  A sterile syringe for every drug user injection: how many injections take place annually, and how might pharmacists contribute to syringe distribution?

Authors:  P Lurie; T S Jones; J Foley
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998

2.  Pharmacists' attitudes about pharmacy sale of needles/syringes and needle exchange programs in a city without needle/syringe prescription laws.

Authors:  A A Gleghorn; G Gee; D Vlahov
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998

3.  Impact of the change in Connecticut syringe prescription laws on pharmacy sales and pharmacy managers' practices.

Authors:  L Wright-De Agüero; B Weinstein; T S Jones; J Miles
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998

4.  Pharmacy access to syringes among injecting drug users: follow-up findings from Hartford, Connecticut.

Authors:  M Singer; H A Baer; G Scott; S Horowitz; B Weinstein
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

5.  Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1998-10-16

6.  HIV incidence among injecting drug users in New York City syringe-exchange programmes.

Authors:  D C Des Jarlais; M Marmor; D Paone; S Titus; Q Shi; T Perlis; B Jose; S R Friedman
Journal:  Lancet       Date:  1996-10-12       Impact factor: 79.321

7.  Syringe exchange and risk of infection with hepatitis B and C viruses.

Authors:  H Hagan; J P McGough; H Thiede; N S Weiss; S Hopkins; E R Alexander
Journal:  Am J Epidemiol       Date:  1999-02-01       Impact factor: 4.897

8.  Access to sterile syringes in Maine: pharmacy practice after the 1993 repeal of the syringe prescription law.

Authors:  P Case; G A Beckett; T S Jones
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998

9.  Prevalence and incidence of hepatitis C virus infection among young adult injection drug users.

Authors:  R S Garfein; M C Doherty; E R Monterroso; D L Thomas; K E Nelson; D Vlahov
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998
  9 in total
  6 in total

1.  Expanded syringe access demonstration program in New York State: an intervention to prevent HIV/AIDS transmission.

Authors:  S J Klein; G S Birkhead; A R Candelas
Journal:  J Urban Health       Date:  2000-12       Impact factor: 3.671

2.  What do pharmacists think about New York state's new nonprescription syringe sale program? Results of a survey.

Authors:  S J Klein; K Harris-Valente; A R Candelas; M Radigan; M Narcisse-Pean; J M Tesoriero; G S Birkhead
Journal:  J Urban Health       Date:  2001-12       Impact factor: 3.671

3.  Addressing urban health in Detroit, New York City, and Seattle through community-based participatory research partnerships.

Authors:  Marilyn M Metzler; Donna L Higgins; Carolyn G Beeker; Nicholas Freudenberg; Paula M Lantz; Kirsten D Senturia; Alison A Eisinger; Edna A Viruell-Fuentes; Bookda Gheisar; Ann-Gel Palermo; Donald Softley
Journal:  Am J Public Health       Date:  2003-05       Impact factor: 9.308

4.  Self-reported participation in voluntary nonprescription syringe sales in California's Central Valley.

Authors:  Robin A Pollini
Journal:  J Am Pharm Assoc (2003)       Date:  2017-08-12

5.  New York City pharmacists' attitudes toward sale of needles/syringes to injection drug users before implementation of law expanding syringe access.

Authors:  P O Coffin; B P Linas; S H Factor; D Vlahov
Journal:  J Urban Health       Date:  2000-12       Impact factor: 3.671

6.  Syringe access for the prevention of blood borne infections among injection drug users.

Authors:  Sharon Stancliff; Bruce Agins; Josiah D Rich; Scott Burris
Journal:  BMC Public Health       Date:  2003-11-21       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.